Forsyth Medical Center 
| Learn more about our current Breast Cancer Clinical Trials. |
 |
||
|
Want to Participate?
If you or someone you know may be interested in participating in a clinical trial, contact us at dmccall@phoa.org or (336) 277-8887.
|
|
|
||
NSABP B-35: ANASTROZOLE VERSUS TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH DCIS, UNDERGOING LUMPECTOMY WITH RADIATION
SWOG S0012: ADRIAMYCIN & CYTOXAN VERSUS WEEKLY ADRIAMYCIN & DAILY ORAL CYTOXAN WITH NEUPOGEN FOR LOCALLY ADVANCED OR INFLAMATORY ( NEO ADJUVANT)
USO 02103: PHASE II, 5FU, EPIRUBICIN & CYTOXAN FOLLOWED BY TAXOTERE & XELODA FOR HIGH RISK, NEO ADJUVANT
USO 01062: PHASE III, ADRIAMYCIN & CYTOXAN FOLLOWED BY TAXOTERE WITH OR WITHOUT XELODA FOR HIGH RISK
USO 00010: PHASE III, EXEMESTANE VERSUS TAMOXIFEN FOLLOWED BY EXEMESTANE FOR POSTMENOPAUSAL , RECEPTOR POSITIVE
CTSU MA.20: PHASE III, REGIONAL RADIATION FOR HIGH RISK, CHEMO OF CHOICE
CTSU 25-02 (TEXT)- TAMOXIFEN & TRIPTORELIN VERSUS EXEMESTANE & TRIPTORELIN IN PREMENOPAUSAL, RECEPTOR POSITIVE
CTSU 24-02 (SOFT) -3 ARM, TAMOXIFEN VERSUS TAMOXIFEN & OFS VERSUS EXEMESTANE & OFS FOR PREMENOPAUSAL ( OFS = OVARIAN FUNCTION SUPRESSION )
CALGB 49907: CYTOXAN, METHOTREXATE & 5FU VERSUS ADRIAMYCIN & CYTOXAN VERSUS XELODA IN OLDER WOMEN WITH HIGH RISK
SWOG S0221: ADRIAMYCIN, CYTOXAN & PEGFILGRASTIM EVERY 2 WEEKS THEN TAXOL VERSUS ADRIAMYCIN, ORAL CYTOXAN & PEGFILGRASTIM WEEKLY THEN TAXOL
